“Pregnant women receiving medication therapy for addiction can be prescribed higher doses of buprenorphine without increasing the risk or severity of neonatal abstinence syndrome (NAS), according to a study published in the Journal of Addiction Medicine.
The study included mother-infant pairs maintained on buprenorphine, with mothers who delivered at the Swedish Medical Center First Hill Campus from January 1, 2000, through April 1, 2016. Mothers had diagnosed opioid dependency and were aged 18 to 53 years. The primary outcomes were requirement of morphine treatment, peak NAS score, peak morphine dose, time to morphine start, days on morphine, and total duration of hospital stay.
Source: ClinicalPainAdvisor.com – July 26, 2018